The Motley Fool

What’s Stopped Me From Buying AstraZeneca Plc Today

Today, I am looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US), and deciding whether to add the company to my personal stocks portfolio.

Patent expiration problems continue to gallop on

AstraZeneca’s half-yearly report released this month showed revenues, on a constant exchange rate, fall 8% in January-June to $12.62bn. This in turn drove core operating profit 16% lower to $4.38bn. The effect of patent expiration across many of its key products moderated in the second quarter, although revenues and core operating profit still fell 4% and 10% in the period.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Promisingly, AstraZeneca announced that its product pipeline had added three promising late-stage assets in core therapeutic areas of cardiovascular/metabolism and respiratory diseases”. The company is undergoing significant transformation plans at its R&D operations across Europe in order to compensate for the loss of key patents and undergird future earnings growth.

But the firm seems to be behind many of its rivals such as GlaxoSmithKline in significantly addressing the issue of exclusivity loss and bringing online new earnings drivers. The new product additions are a promising development in the firm’s transformation plan, but with new drugs taking years to hit the shelves from initial testing, investors should be braced for more near-term pain.

Earnings slump predicted to last through 2014

City forecasters expect last year’s 12% earnings slump to remain in vogue well into the medium term. Earnings per share are expected to slip 19% this year, to 335p, before falling a further 6% in 2014 to 316p.

The pharma play currently changes hands on a P/E ratio of 9.7 and 10.3 for 2013 and 2014 respectively, figures anchored around the widely-regarded bargain watermark of 10 times prospective earnings. But in my opinion this simply reflects the dearth of earnings catalysts at the firm and thus strong likelihood for shareholder returns to encounter severe pressure.

Pick up the prescription for bountiful gains

On the dividend front, analysts have pencilled in a full-year payout of 285 US cents for 2013, with a rise to 287 cents expected next year. These payments carry yields of 5.7%, comfortably beating the 3.1% FTSE 100 average and aggregate reading of 2.4% for its pharmaceuticals and biotechnology rivals.

AstraZeneca kept the dividend on hold at 280 cents last year as earnings crumbled, and I believe that future dividends could come under fire should further earnings pressure materialise as expected. In my opinion the pharma giant represents too much of a gamble for investors at present, and I will be waiting for more progress from its product pipeline before I consider parting with my cash.

So although AstraZeneca is not a candidate for the savvy investor’s stocklist at present, I believe that you should check out this exclusive, in-depth report about another FTSE 100 high-income opportunity ready to dispense lucrative shareholder returns.

The blue chip in question offers a prospective dividend yield comfortably north of 5%, and has been declared “The Motley Fool’s Top Income Stock For 2013“! Click here to download the report now — it’s absolutely free and comes with no further obligation.

> Royston does not own shares in AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.